Notably, even fewer studies have characterised HER2, variably determined by either FISH or immunohistochemistry within non-BRCA1/2 (so-called BRCAX) familial breast cancers, with nine small studies showing a wide range of HER2 positivity (9–60%) [42]. This evidence concerns the gene ERBB2 and breast carcinoma.